Oppenheimer Asset Management Inc. Has $7.76 Million Stock Holdings in Pfizer Inc. $PFE

Oppenheimer Asset Management Inc. lessened its holdings in Pfizer Inc. (NYSE:PFE) by 1.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 319,906 shares of the biopharmaceutical company’s stock after selling 3,565 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Pfizer were worth $7,755,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in PFE. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer during the first quarter valued at about $27,000. Curio Wealth LLC boosted its position in Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,098 shares during the period. Bayforest Capital Ltd acquired a new position in shares of Pfizer during the first quarter worth $28,000. North Capital Inc. acquired a new position in shares of Pfizer during the first quarter worth $28,000. Finally, Harbor Asset Planning Inc. acquired a new position in shares of Pfizer during the second quarter worth $29,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of NYSE PFE opened at $24.76 on Tuesday. The firm’s 50-day moving average price is $24.86 and its 200-day moving average price is $24.21. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $29.17. The firm has a market capitalization of $140.75 billion, a P/E ratio of 13.17, a P/E/G ratio of 0.82 and a beta of 0.55. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the prior year, the business earned $0.60 EPS. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio is presently 91.49%.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. UBS Group reaffirmed a “neutral” rating and set a $28.00 target price on shares of Pfizer in a report on Wednesday, October 1st. Bank of America lifted their price objective on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Finally, Morgan Stanley dropped their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research report on Friday, October 10th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus target price of $28.13.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.